**SUPPLEMENTAL DIGITAL CONTENT - TABLES**

Table S1: Number of Treatment Emergent Related Adverse Events by Treatment Group

| Relatedness | Grade | 500 mg n | | 1000 mg n | | 2000 mg n | | Overall n | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |
| Drug-related | 1 |  | 9 |  | 16 |  | 31 |  | 56 |
|  | 2 |  | 5 |  | 5 |  | 16 |  | 26 |
|  | 3 |  | 1 |  | 1 |  | 6 |  | 8 |
|  | 4 |  | 0 |  | 0 |  | 1 |  | 1 |

**TABLE S2:** Summary Statistics for the Assessment of Dose Proportionality and PK Linearity of SLC-0111 in Subjects with Advanced Solid Tumors during Cycle 1 Following Single Dose (Day 1; N= 10 Subjects) and Multiple Doses (Day 28; N=10) of SLC-0111 using a Power-Law Model

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Day** | **Parameter** | **Slope** | | | **Dose Proportionality** |
| **Mean**  **(SE)** | **90% CI** | **P-value**  **(Slope = 1)** |
|  |  |  |  |  |  |
| 1 | Cmax | 0.1421 ( 0.4194) | -0.6379 to 0.9222 | 0.0750 | Yes |
|  | AUC(0-24) | 0.5295 ( 0.4216) | -0.2547 to 1.314 | 0.2968 | Yes |
|  |  |  |  |  |  |
| 28 | Cmax | 0.6083 ( 0.2782) | 0.09083 to 10126 | 0.1967 | Yes |
|  | AUC(0-24) | 0.7866 ( 0.3224) | 0.1870 to 1.386 | 0.5265 | Yes |
|  |  |  |  |  |  |